[HTML][HTML] Towards hepatitis C virus elimination: Egyptian experience, achievements and limitations

D Omran, M Alboraie, RA Zayed, MN Wifi… - World journal of …, 2018 - ncbi.nlm.nih.gov
Worldwide, more than one million people die each year from hepatitis C virus (HCV) related
diseases, and over 300 million people are chronically infected with hepatitis B or C. Egypt …

RETRACTED ARTICLE: Efficacy of combined Sofosbuvir and Daclatasvir in the treatment of COVID-19 patients with pneumonia: A multicenter Egyptian study

M El-Bendary, S Abd-Elsalam, T Elbaz… - Expert Review of Anti …, 2022 - Taylor & Francis
Statement of Retraction We, the Editors and Publisher of Expert Review of Anti-Infective
Therapy, have retracted the following article: Mahmoud El-Bendary, Sherief Abd-Elsalam …

Alterations of the treatment-naive gut microbiome in newly diagnosed hepatitis C virus infection

S Sultan, M El-Mowafy, A Elgaml… - ACS Infectious …, 2020 - ACS Publications
Gut microbiota dysbiosis has been linked to many heath disorders including hepatitis C virus
(HCV) infection. However, profiles of the gut microbiota alterations in HCV are inconsistent …

Safety and efficacy of combined sofosbuvir/daclatasvir treatment of children and adolescents with chronic hepatitis C genotype 4

TY Abdel Ghaffar, S El Naghi… - Journal of viral …, 2019 - Wiley Online Library
Direct‐acting antivirals have become available for treating chronic HCV (hepatitis C virus)
infection in adults and, recently, in children at least 12 years old. Our aim was to investigate …

Predictors for fibrosis regression in chronic HCV patients after the treatment with DAAS: results of a real-world cohort study

H Soliman, D Ziada, M Salama… - … Metabolic & Immune …, 2020 - ingentaconnect.com
Introduction: The goal of treatment of chronic hepatitis C (HCV) is viral eradication. However,
obtaining histological regression is even more important, because it will reduce the overall …

Hepatitis C virus: efficacy of new DAAs regimens

AA Mohamed, NETR El-Toukhy… - … Current Drug Targets …, 2020 - ingentaconnect.com
Background: HCV treatment showed dramatical change due to the introduction of potent,
strong, direct antiviral drugs. Before the appearance of Direct-acting antivirals, multiple …

[HTML][HTML] Correlation between IL28B/TLR4 genetic variants and HCC development with/without DAAs treatment in chronic HCV patients

GM Salum, RM Dawood, M Abd el-Meguid, NE Ibrahim… - Genes & …, 2020 - Elsevier
Abstract In Egypt, Sofosbuvir (SOF) in combination with Dataclasvir (DCV) is the broadly
used DAAs with excellent therapeutic profile. This study is designed to explore the relation …

IL-1α correlates with severity of hepatitis C virus-related liver diseases

AK Tawfik, AM Amin, M Yousef… - Journal of …, 2018 - Taylor & Francis
Background and aims Immunoregulatory cytokines influence the persistence of hepatitis C
virus (HCV) chronic infection and the extent of liver damage. Interleukin-1 (IL-1) plays an …

[HTML][HTML] End treatment response and sustained viral response in patients with hepatitis C virus receiving sofosbuvir and daclatasvir

AS Rahman, M Amir, Q Jamal, M Riaz, K Fareed… - Cureus, 2023 - ncbi.nlm.nih.gov
Objective The main purpose of this study was to determine the end treatment response
(ETR) and sustained viral response (SVR) in hepatitis C virus (HCV) patients receiving …

Screening a nation for hepatitis C virus elimination: a cross-sectional study on prevalence of hepatitis C and associated risk factors in the Rwandan general population

J Umutesi, CY Liu, MJ Penkunas, JD Makuza… - BMJ open, 2019 - bmjopen.bmj.com
Objectives We analysed data collected during programmatic screening activities conducted
in 2017 to describe hepatitis C virus (HCV) seroprevalence in the general population and …